Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immune cell therapy takes on tough lymphoma

NCT ID NCT06334991

Recruiting now Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 8 times

Summary

This early-phase study tests a new treatment called CD19 t-haNK, which uses specially designed immune cells to target and kill cancer cells. It is for 10 adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goal is to check the safety of these cells when given alone or with the drug rituximab.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Albert Cellular Therapy

    RECRUITING

    Pretoria, Gauteng, 0044, South Africa

    Contact Email: •••••@•••••

  • Dr. Jackie Thomson Inc.

    RECRUITING

    Johannesburg, Gauteng, 2193, South Africa

    Contact Email: •••••@•••••

    Contact

  • FARMOVS

    RECRUITING

    Bloemfontein, Free State, 9301, South Africa

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED